Abstract: The present invention relates to fusion molecules that have binding specificity for pyoverdine type I, II and III and pyochelin and can be used in various applications, including diagnostic and/or therapeutic applications, for example, to inhibit or reduce growth of P. aeruginosa and/or to prevent or treat P. aeruginosa biofilm infection as well as diseases or disorders associated with P. aeruginosa biofilm infection. The present invention also concerns methods of producing the fusion molecules described herein as well as compositions and kits comprising such fusion molecules. The present invention further relates to nucleic acid molecules encoding the fusion molecules described herein.

Abstract: The present invention relates to fusion molecules that have binding specificity for pyoverdine type I, II and III and pyochelin and can be used in various applications, including diagnostic and/or therapeutic applications, for example, to inhibit or reduce growth of P. aeruginosa and/or to prevent or treat P. aeruginosa biofilm infection as well as diseases or disorders associated with P. aeruginosa biofilm infection. The present invention also concerns methods of producing the fusion molecules described herein as well as compositions and kits comprising such fusion molecules. The present invention further relates to nucleic acid molecules encoding the fusion molecules described herein.

Abstract: The present invention relates to fusion molecules that have binding specificity for pyoverdine type I, II and III and pyochelin and can be used in various applications, including diagnostic and/or therapeutic applications, for example, to inhibit or reduce growth of P. aeruginosa and/or to prevent or treat P. aeruginosa biofilm infection as well as diseases or disorders associated with P. aeruginosa biofilm infection. The present invention also concerns methods of producing the fusion molecules described herein as well as compositions and kits comprising such fusion molecules. The present invention further relates to nucleic acid molecules encoding the fusion molecules described herein.

Abstract: The present invention relates to fusion molecules that have binding specificity for pyoverdine type I, II and III and pyochelin and can be used in various applications, including diagnostic and/or therapeutic applications, for example, to inhibit or reduce growth of P. aeruginosa and/or to prevent or treat P. aeruginosa biofilm infection as well as diseases or disorders associated with P. aeruginosa biofilm infection. The present invention also concerns methods of producing the fusion molecules described herein as well as compositions and kits comprising such fusion molecules. The present invention further relates to nucleic acid molecules encoding the fusion molecules described herein.

Abstract: The invention is related to a process for preparing compounds of the formula IV by means of conversion of aromatic aldehydes of the formula I using ?-ketoximes of the formula II via N-oxides of the formula III to halomethyloxazoles of the formula IV, wherein R1, R2, R3, R4, R5, R6, R7, R8, X1, X2, X3, o, n1 and n2 are as defined herein.

Abstract: The invention relates generally to a process for preparing diarylcycloalkyl derivatives of the formula (I). wherein the respective R-group substituents are defined herein. These compounds of formula (I) are activators for peroxisome proliferator-activated receptors (PPAR activators) which are useful in the therapeutic treatment of a number of diseases and disorders of the central nervous system such as multiple sclerosis, Parkinson's Disease, psychiatric disorders and the like. The present invention is a novel process for preparing PPAR activators of the formula (I) which do not have the disadvantages of the processes known in the prior art. In particular, a process is provided with which the PPAR activators of formula (I) can be prepared in a suitable enantiomeric excess, i.e. high enantioselectivity, without the need for subsequent chiral chromatography.

Abstract: The invention is related to a process for preparing compounds of the formula IV by means of conversion of aromatic aldehydes of the formula I using ?-ketoximes of the formula II via N-oxides of the formula III to halomethyloxazoles of the formula IV, wherein R1, R2, R3, R4, R5, R6, R7, R8, X1, X2, X3, o, n1 and n2 are as defined herein.

Abstract: The present invention is comprised of improved methods in the preparation of oxazoles which results in higher yields with less impurities and contaminants. Oxazoles constitute valuable intermediates in the synthesis of pharmaceutically active substances such as, for example peroxisome proliferator activated receptor (PPAR) agonists which are pharmaceutical actives which can have a positive influence on both lipid and glucose metabolism.

Abstract: The present invention is directed to compounds of Formula III wherein the R1-R7 groups or substituents are defined herein. The present invention also comprises improved methods in the preparation of oxazoles in which the compounds of Formula III are intermediates and which results in higher yields with less impurities and contaminants. Oxazoles constitute valuable intermediates in the synthesis of pharmaceutically active substances such as, for example peroxisome proliferator activated receptor (PPAR) agonists which are pharmaceutical actives which can have a positive influence on both lipid and glucose metabolism.

Abstract: The present invention is comprised of improved methods in the preparation of oxazoles which results in higher yields with less impurities and contaminants. Oxazoles constitute valuable intermediates in the synthesis of pharmaceutically active substances such as, for example peroxisome proliferator activated receptor (PPAR) agonists which are pharmaceutical actives which can have a positive influence on both lipid and glucose metabolism.

Abstract: The invention relates generally to intermediate compounds derived during the process for preparing diarylcycloalkyl derivatives which are activators for peroxisome proliferator-activated receptors (PPAR activators) and are therefore useful in the therapeutic treatment of a number of diseases and disorders of the central nervous system such as multiple sclerosis, Parkinson's Disease, psychiatric disorders and the like. The intermediate compounds of the present invention are defined structurally by the formulae (Ia): and formula (II): wherein the respective substituent groups are defined herein.

Abstract: The invention relates generally to a process for preparing diarylcycloalkyl derivatives of the formula (I). wherein the respective R-group substituents are defined herein. These compounds of formula (I) are activators for peroxisome proliferator-activated receptors (PPAR activators) which are useful in the therapeutic treatment of a number of diseases and disorders of the central nervous system such as multiple sclerosis, Parkinson's Disease, psychiatric disorders and the like. The present invention is a novel process for preparing PPAR activators of the formula (I) which do not have the disadvantages of the processes known in the prior art. In particular, a process is provided with which the PPAR activators of formula (I) can be prepared in a suitable enantiomeric excess, i.e. high enantioselectivity, without the need for subsequent chiral chromatography.

Abstract: The invention relates to chiral Mannich bases of formula (I), chiral 1,3-amino alcohols of formula (II) derived therefrom, wherein R1, R2, R3, R4 and R5 are as defined herein, and to processes for preparing Mannich salts of formula (III) containing a chiral anion Y*? and compounds of formulae (I) and (II), wherein R1, R2, R3, R4, R5 and Y*? are as defined herein.

Abstract: The invention relates to chiral Mannich bases of formula (I), chiral 1,3-amino alcohols of formula (II) derived therefrom, wherein R1, R2, R3, R4 and R5 are as defined herein, and to processes for preparing Mannich salts of formula (III) containing a chiral anion Y*− and compounds of ormulae (I) and (II), wherein R1, R2, R3, R4, R5 and Y*− are as defined herein.

Abstract: A steering column for a motor vehicle having a gear box of an electric power assist apparatus in front of the steering column. The steering column includes a rigid mast jacket consisting of a short tubular sleeve and a bracket attached to the tubular sleeve having a pair of laterally separated guides straddling the gear box. A pair of lugs on the gear box cooperate with a pair of elongated slots in the guides in connecting the mast jacket to the gear box for vertical pivotal movement and for linear translation. A longitudinally collapsible steering shaft is rotatably supported on the tubular sleeve with a steering hand wheel at one end and a flexible coupling at the other end connecting the steering shaft to an input shaft on the gear box. The tubular sleeve is connected to the vehicle body by a clamp which releases the tubular sleeve for a collapse stroke of the mast jacket. The mast jacket protects the steering shaft against beam bending during the collapse stroke.

Abstract: A connection between a collapsible mast jacket of an energy absorbing steering column and a body of a motor vehicle including a mounting bracket on the mast jacket having an attachment flange perpendicular to a longitudinal centerline of the steering column, an aperture in the attachment flange, a plastic bushing captured in the aperture, and a fastener operative to rigidly clamp the plastic bushing to the body of the motor vehicle. The plastic bushing fractures in response to an impact on the steering column to release the mounting bracket. In a preferred embodiment, retention between the attachment flange and the plastic bushing is effected by an edge of the aperture in the attachment flange seated in an annular outside groove in the plastic bushing.

Abstract: An energy-absorbing motor vehicle steering column including a housing supported on a body structure of the vehicle for linear translation in a collapse direction and an energy absorber which converts into work a fraction of the kinetic energy of an impact on the steering column. The energy absorber includes a bare flat metal ribbon, i.e., without friction-reducing coating or lubrication, preformed to define a pair of parallel straight sections and a lateral web between the straight sections. The ribbon is seated edge-wise on a horizontal wall of the steering column housing with the straight sections in a pair of longitudinal guide channels and the lateral web looped over a pair of laterally spaced bare anvils on the housing and wedged between the bare anvils and an abutment on the body structure on the other side of the lateral web from the anvils.